PURSUANT TO COMPLETION OF DUE DILIGENCE, WELLBEING WILL DIVEST ITS EQUITY STAKE IN IRP Wellbeing Digital Sciences Inc. (“Wellbeing” or the...
Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company...
The psilocybin 1.5mg capsules are available for potential therapeutic use in non-ASD clinical trials, including but not limited to diabetes...
With the Company’s extensive experience in this sector, we are eager to replicate the growth and profitability success of our clinics at...
New Clinical Facility in London, Ontario Accelerates Research and Innovation Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”...
Revenue Exceeded $1.1 Million for the Period Ended July 31, 2022 Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI...
We are delighted to add Najla Guthrie to this highly respected council, representing the leading voices in the emerging sector of psychedelic...
KGK client, Hofseth Biocare ASA, is yet again part of an Exclusive Short-List of Companies to Have Successfully Notified FDA while receiving a No...
IRP Health continues to focus on enriching the lives of its patients and raising the bar for outstanding mental healthcare Wellbeing Digital...
Subsidiary KGK has $17 million of future revenue as of end of June, which we project to complete in the next 12 to 18 months through our research...
KGK to conduct Phase II clinical trial to test the efficacy of psilocybin on treatment resistant PTSD Wellbeing Digital Sciences Inc...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads